Tandem Diabetes Care (TNDM) Free Cash Flow (QoQ) (2013 - 2026)
Tandem Diabetes Care (TNDM) Free Cash Flow (QoQ) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.73 Bn | 176.43 Bn | 6.27 Bn |
| 2 | Stryker | 129.05 Bn | 126.17 Bn | 3.81 Bn |
| 3 | Medtronic | 108.52 Bn | 99.30 Bn | 6.41 Bn |
| 4 | Boston Scientific | 68.63 Bn | 67.18 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 48.43 Bn | 44.76 Bn | 1.29 Bn |
| 6 | Dexcom | 28.36 Bn | 27.24 Bn | 750.30 Mn |
| 7 | GE HealthCare Technologies | 28.14 Bn | 25.85 Bn | 1.98 Bn |
| 8 | Smith & Nephew | 26.89 Bn | 26.32 Bn | - |
| 9 | Koninklijke Philips | 24.25 Bn | 21.12 Bn | 2.07 Bn |
| 10 | Tandem Diabetes Care | 1.14 Bn | 567.87 Mn | 136.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 54.19% |
| Dec 31, 2025 | 179.06% |
| Sep 30, 2025 | 48.37% |
| Jun 30, 2025 | 64.20% |
| Mar 31, 2025 | -176.49% |
| Dec 31, 2024 | 28.93% |
| Sep 30, 2024 | 265.90% |
| Jun 30, 2024 | -15.83% |
| Mar 31, 2024 | -25.31% |
| Dec 31, 2023 | -159.47% |
| Sep 30, 2023 | 209.81% |
| Jun 30, 2023 | 49.55% |
| Mar 31, 2023 | -587.24% |
| Dec 31, 2022 | -77.01% |
| Sep 30, 2022 | 289.18% |
| Jun 30, 2022 | -52.88% |
| Mar 31, 2022 | -29.52% |
| Dec 31, 2021 | -45.08% |
| Sep 30, 2021 | 18.77% |
| Jun 30, 2021 | 0.30% |